mRNA's second act arrives, and it looks like a flu shot

In August 2026, the FDA approved mFlusiva, Moderna's mRNA influenza vaccine, making it the first mRNA flu shot to clear the agency. The approval is the technology's first genuine second act since the COVID windfall: not an emergency authorization on a pandemic clock, but a routine seasonal product judged against the ordinary bar.

The pipeline behind it is already more interesting than the approval itself. A combined COVID-plus-influenza mRNA vaccine cleared its phase 3 endpoints, and an H5 bird flu candidate is running in pandemic-preparedness trials. If the combination works commercially, the annual mRNA shot becomes the delivery vehicle for whatever respiratory threat the decade produces next.

Why flu is the hard exam

Influenza was always the tougher test than COVID, and the field knew it. mRNA's pandemic advantage was speed: sequence to clinic in weeks. Flu's problem was never speed. It is antigenic drift, pre-existing immunity in every arm receiving the shot, and a decades-old incumbent supply chain that prices a flu dose in tens of dollars. An mRNA flu vaccine does not need to be good. It needs to be better than a product that costs a tenth as much and that seniors already line up for.

The approval for older adults is the commercially decisive detail, because that is the cohort where flu kills and where ACIP recommendation, reimbursement and uptake actually flow. If the at-risk population shows a real efficacy edge in the coming seasons, the pricing conversation changes from premium product to standard of care. If it does not, mRNA flu becomes a niche.

The combination is the real product

The strategic endgame is not flu alone. It is the annual respiratory booster: flu, COVID and eventually RSV in one vial, updated each season like software. The clinical data supporting the flu-COVID combination has been promising, and the operational logic is compelling: one shot, one supply chain, one clinic visit. The obstacle is not virology but the vaccination machinery itself, from committee scheduling to fridge space at the pharmacy. The combination vaccine is a product that requires the health system to reorganize around it.

What to watch

Three checkpoints will decide whether mRNA's second act has staying power. First uptake: a first season of mFlusiva sales against the traditional cohort's volumes. Second, the regulatory path of the flu-COVID combination, which is the margin story. Third, whether the H5N1 preparedness trials convert into stockpile contracts, which is the option value that made investors forgive the COVID hangover in the first place.

The pandemic chapter proved mRNA could be built in a hurry. The flu chapter asks a harder question: can it be built to a price, on a schedule, every year, against an incumbent nobody hates. That is a real business, not an emergency. It is also the first test of the technology that does not excuse itself with a crisis.

The brief: The first mRNA flu vaccine is approved for older adults, with a flu-COVID combination and an H5N1 preparedness program behind it. The technology's post-COVID chapter now depends on price, uptake and the annual booster logic. Watch the combination's filing.